INCYTE CORP (INCY)
US45337C1027 - Common Stock
Don't overlook NASDAQ:INCY—a stock with solid growth prospects and a reasonable valuation.
In the world of growth stocks, NASDAQ:INCY shines as a value proposition.
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
Equitable Holdings Larger Than S&P 500 Component Incyte
When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Don't overlook INCYTE CORP (NASDAQ:INCY)—it's a hidden gem with strong fundamentals and an attractive price tag.
Discover the top S&P500 movers in Monday's pre-market session and stay informed about market dynamics.
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.
Incyte Enters Oversold Territory (INCY)
Incyte to Report First Quarter Financial Results
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
First Week of May 17th Options Trading For Incyte (INCY)
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
Don't fall for the siren song of penny stocks. Rather, fill your portfolio with companies that have a proven track record of success.
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth.
FDA accepts Incyte application for graft-versus-host disease drug (NASDAQ:INCY)
The FDA has accepted Incyte’s (INCY) market application for priority review of its drug candidate axatilimab for the treatment of chronic graft-versus-host disease. Read more here.
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.
Incyte stock a new Buy at Jefferies (NASDAQ:INCY)
Jefferies starts coverage of Incyte (INCY) with a Buy rating, citing its diversification into dermatology as bestseller Jakafi faces patent cliff. Read more here.
Bullish Two Hundred Day Moving Average Cross - INCY
Exit Now! 3 Biotech Stocks to Sell in February 2024
These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability.
Incyte to Present at Upcoming Investor Conference
JMP cuts Incyte to market perform, cites need for acquisition (NASDAQ:INCY)
JMP has downgraded Incyte (INCY) to market perform, asserting that the company will likely need an acquisition to ensure its current cash flow. In its note, the
Commit To Buy Incyte Corporation At $50, Earn 5.6% Annualized Using Options
Notable Friday Option Activity: AMGN, INCY, MU
Pancreatic Cancer Treatments Poised for Major Advances in 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END
Pancreatic Cancer Treatments Poised for Major Advances in 2024
/PRNewswire/ -- USA News Group - One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly...